HLA-C and neoplasm: It is expected that more tumor mutations will result in more MHC-binding neoantigens that are responsible for mediating tumor immune infiltration and chemotherapy response (Igarashi et al., 2002; Gubin et al., 2014; Snyder et al., 2014; Yadav et al., 2014).